IndradeepBhattacharya (Indra)

Associate

London + 44.20.7039.5277

Connect:

Share

Indra Bhattacharya has more than eight years of experience in high-value IP disputes across a range of industry sectors, including pharmaceuticals, biotechnology, medical devices, and consumer technology and electronics. He is also experienced in commercial IP matters and in technology-rich corporate transactions.

Indra has acted for some of world's leading pharmaceutical and medical device companies, including Abbott, Actavis, Celgene, and Merck in multijurisdictional high-profile patent disputes in the United Kingdom, Asia, and Australia. He is part of the Firm's award winning life sciences practice and regularly acts in transactions in the pharmaceutical field and advises on freedom to operate issues. He also has acted on trademark, design rights, and breach of confidence cases in the technology and retail sectors. He is experienced litigating before English and Australian courts.

In addition, he has significant regulatory experience having spent time in-house in pharmaceutical and research institutions. This includes pharmaceutical and medical devices regulation along with food safety and hygiene issues. He also regularly assists clients on investigations with regulators including the EMA and MHRA.

Indra holds a first class degree in law and is technically qualified with a degree in genetics and biochemistry. He has previously lectured on intellectual property law.

Experience

  • Macquarie sold Condor FerriesJones Day advised Macquarie Infrastructure and Real Assets in the sale of Condor Ferries, an operator of lifeline freight and passenger ferry services between Guernsey, Jersey, the United Kingdom, and the Port of St. Malo in France, to a consortium of Columbia Threadneedle European Sustainable Infrastructure Fund (ESIF) and Brittany Ferries.
  • Sumitomo Heavy Industries invests $46 million into Highview PowerJones Day advised Sumitomo Heavy Industries, Ltd., a technology leader in industrial machinery and environmental and power technologies, in its $46 million investment into Highview Power, a global leader in long-duration energy storage solutions.
  • True Capital invests £26 million in Soulfresh GroupJones Day represented True Capital Limited in connection with their £26 million investment in the Soulfresh Group, a food and beverage group headquartered in Melbourne, Australia providing a range of produce with a health and sustainability focus including fermented beverages and plant-based food and drinks.
  • Kubota enforces its intellectual property rights to prevent sales of unauthorized grey goods products in UKJones Day advised Kubota UK Limited, a leading tractor and heavy equipment manufacturer, regarding the enforcement of its intellectual property rights in relation to imports and sales of unauthorized grey good products in the United Kingdom.
  • INVISTA sells German HVA polymer asset to Indorama VenturesJones Day advised INVISTA in the sale of INVISTA Resins & Fibers GmbH to Indorama Ventures Public Company Limited.
  • ANSYS acquires Granta Design LimitedJones Day advised ANSYS, Inc., the global leader and innovator of engineering simulation software, in their acquisition of Granta Design, the premier provider of materials information technology, and Granta Design Limited has become a wholly-owned subsidiary of ANSYS.
  • Huadong Medicine announces £169 million (US$222 million) takeover offer for and acquisition of Sinclair Pharma PlcJones Day advised Huadong Medicine Co. Ltd. ("HMC") and its subsidiary, Huadong Medicine Aesthetics Investment (HongKong) Limited ("Huadong"), on Huadong's takeover offer for and acquisition of Sinclair Pharma Plc with a total value of approximately £169 million (US$222 million).
  • Celgene defends its leading product Revlimid® against patent revocation actions in UKJones Day acted for Celgene Corporation in multiple cases brought by Accord Healthcare in the UK High Court (patents court) in relation to Celgene's patents concerning its best-selling drug, Revlimid®.
  • True Capital Ltd completes buyout of Cut4ClothJones Day represented True Capital Ltd in connection with its buyout of Cut4Cloth Ltd. trading as Frugi, a retailer of organic children's clothing, toys, and accessories, alongside existing management.
  • CVC Capital Partners acquires Teva's International Women's Health assets for $703 millionJones Day advised CVC Capital Partners in its $703 million acquisition of Teva Pharmaceutical Industries Ltd's International (non-US), Women's Health assets.
  • L1 Retail acquired Holland & Barrett from The Nature's Bounty Co. and The Carlyle Group for £1.77 billion (US$2.25 billion)Jones Day advised L1 Retail, the retail investment arm of LetterOne, on its acquisition of Holland & Barrett, Europe's largest health and wellness retailer, from The Nature's Bounty Co. and The Carlyle Group for £1.77 billion (US$2.25 billion).
  • Loxo Oncology acquires drug development program from administrators of RedXJones Day advised biopharmaceutical company, Loxo Oncology, Inc., in connection with its $40 million acquisition of a drug development program aimed at treating leukemia from the administrators of RedX Pharma Plc.
  • Funds managed by Invesco Asset Management Limited invest in Lamellar Biomedical LimitedJones Day advised Invesco Asset Management in connection with its investment alongside Scottish Enterprises and others in the capital raise by Lamellar Biomedical Limited, a privately held Scottish biotechnology company.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Riverside invests in FadataJones Day advised The Riverside Company in connection with its investment in Fadata, a provider of software solutions for international providers of life and property & casualty insurance. Charles Taylor, a London-based global insurance service business, acted as co-investor.
  • Funds managed by Invesco Asset Management Limited invest in Mereo BioPharma GroupJones Day advised Invesco Asset Management managed funds on their investment alongside Woodford Investment Management in the $119 million (c. £76.5 million) capital raise by Mereo BioPharma Group Ltd. Novartis Pharmaceuticals, through shares issued in consideration for the acquisition of clinical-stage development programs, will also hold an equity stake in Mereo.
  • Idenix asserts patent infringement against Gilead in UK related to Sovaldi® and Harvoni®Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in the Patents Court and Court of Appeal in patent litigation against Gilead in the UK over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
    • View All

    January 2020 Newsletters

    Vital Signs: Digital Health Law Update | Winter 2020

    June 2019 Commentaries

    Protecting Your Trade Secrets in the UK

    January 2019 Jones Day Publications

    Second Medical Use Patents in Europe: Are UK and Germany Swapping Approaches?

    June 2017 Jones Day Publications

    Guidance for European MA Holders to Prepare for Brexit, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    Senators Urge the Administration to Certify Imports of Prescription Drugs from Canada, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    New French Decree Clarifies the Scope of Biomedical Research, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2018 Jones Day Publications

    EU Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    EMA Green Lights New EudraVigilance System for Adverse Reactions, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    EMA Calls for Public Consultation on Clinical Trial Protocol, Pharmaceutical & Medical Device Update, Vol. IV, Issue III
    View All

    Additional Publications

    • September 30, 2015
      Approach to '2nd Medical Use' Claims Varies Across EU, Law 360
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.